Licensing · Global (LMICs) · Announced 5 Aug 2026
MSD → 7 generic manufacturers
MSD has granted royalty-free voluntary licences for its once-monthly HIV prevention pill alimatravir to seven generic makers — three of them African: Aspen, Quality Chemical Industries and Universal Corporation — covering 129 countries before Phase 3 has even read out.
Parties: MSD (Merck & Co.) (United States) → 7 generic manufacturers (Aspen, Quality Chemical Industries, Universal Corporation, Aurobindo, Cipla, Emcure, Viatris)
- Deal type
- Licensing
- Value
- See terms
- Territory
- 129 countries, including high-HIV-burden countries in Sub-Saharan Africa
- Therapeutic area
- Infectious Disease
- Asset
- Alimatravir (MK-8527) — investigational once-monthly oral HIV prevention pill (Phase 3); royalty-free voluntary licences for 129 countries
- Announced
- 5 Aug 2026
Our analysis
Why this matters
MSD (Merck & Co.) has signed royalty-free voluntary licensing agreements with seven generic manufacturers for alimatravir (MK-8527), an investigational once-monthly oral pill for HIV prevention now in Phase 3. Three of the seven are African — Aspen Pharmacare (South Africa), Quality Chemical Industries (Uganda) and Universal Corporation (Kenya) — alongside Aurobindo, Cipla, Emcure and Viatris. The licences cover 129 countries.
Two things are unusual. The licences were signed before the trials finished, so generic supply can be ready at approval rather than years later; and almost half of the licensees are African manufacturers, which makes this one of the most significant HIV technology transfers to the continent's own industry. For Sub-Saharan Africa, where most new HIV infections occur, local supply of a monthly prevention pill would change both access and the economics of PrEP programmes.
The full analysis is free to read with a work email on this page.
Source: UNAIDS press release